Form 4 for TEVA TEVA PHARMACEUTICAL INDUSTRIES LTD
Accepted 2026-05-07 16:01:55 ET · period of report 2026-05-05 · accession 0001193125-26-211833 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026-05-07 16:01 | 2026-05-05 | TEVA | Daniell Richard | EVP, Europe Commercial | S - Sale | $35.40 | -30.0K | 55.8K | -35% | -$1.06M |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Ordinary Shares | 2026-05-05 | S | D | 30,000 | $35.40 | 55,755 | D | — | — | (F1) The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. |